Latha Alaparthi, MD, gastroenterologist at Gastroenterology Center of Connecticut, talks about lessons she has learned from being a woman in a medical leadership position and what she hopes to teach others at the Women in GI Luncheon at Digestive Disease Week (DDW) 2022.
Latha Alaparthi, MD, gastroenterologist at Gastroenterology Center of Connecticut, was recently named the first first female president and chair of the board of directors of the Digestive Health Physicians Association, and will be speaking at the Women in GI Luncheon at Digestive Disease Week (DDW) 2022. DDW 2022 will be held virtually and in San Diego, California, from May 21 to 24.
Transcript
Can you give a preview of what you’ll be discussing at the Women in GI Luncheon at DDW 2022?
I want to make sure that anyone that's even beginning in a leadership role realize that some of the core aspects that any leader needs to learn don't change and no matter where you are with your seniority, which is really understanding what your core principles are and adhering to them no matter where you are in your leadership level.
One of the biggest things that I found useful over the years is introspecting—introspecting on what your strengths are, where your weaknesses are, and really acknowledging them and building on your strengths and wherever your weaknesses are, finding your colleagues or employees that can help you with those and make sure that you have resources that can help you with those.
Lastly, it's easier said than done, but to build resilience, it's so important. Just because I'm in a senior position in an organization doesn't mean I don't get questioned every day on my abilities or along the lines, and you need to know how to answer, you need to know how to conduct yourself. There is also the impostor syndrome and the self doubt, which always plagues women, which I don't take as a negative thing. I think it always makes me better. But it's important to know what you're good at or not good at and build that strength to be able to answer. That's what I'm hoping to focus on. I'm hoping that that actually makes people feel like okay, I'm not alone.
Is there anything else you're looking forward to talking about at DDW 2022?
One of the things that we're talking about at DDW, or at least hoping to promote, is how to help early career physicians look at different job opportunities in private practice, because that's not something that we readily have available. Also to look at the pros and cons and really learn what they get into, and eventually we're hoping to create processes or pathways so that they feel mentored and understand the business. When I joined private practice, I really had no understanding of exactly how the business runs or what it takes. People become partners within 2 or 3 years, and they take on risks without understanding the business, and I think putting something in place as an educational process will be really useful, so we're hoping to be able to do that.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More